DCMIC
MRSN

Decheng Capital Management III (Cayman)’s Mersana Therapeutics MRSN Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$1.15M Hold
36,171
– – 0.38% 23
2023
Q2 		$2.98M Hold
36,171
– – 0.93% 19
2023
Q1 		$3.72M Hold
36,171
– – 1.5% 15
2022
Q4 		$5.3M Hold
36,171
– – 1.98% 14
2022
Q3 		$6.11M Hold
36,171
– – 2.22% 13
2022
Q2 		$4.18M Hold
36,171
– – 1.58% 16
2022
Q1 		$3.61M Buy
+36,171
New +$4.23M 1.11% 17

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s MRSN Position: Q3 2023 in Review

Decheng Capital Management III (Cayman) held its Mersana Therapeutics (MRSN) position steady in Q3 2023 at 36,171 shares worth $1.15M. The position accounts for 0.38% of the portfolio, ranked #23.

Decheng Capital Management III (Cayman) first reported a position in MRSN in Q1 2022 and has held it in 7 quarters since. The position peaked at $6.11M in Q3 2022. 128 funds tracked by Wall St. Rank hold MRSN as of Q3 2023.

  • Decheng Capital Management III (Cayman) held 36,171 shares of Mersana Therapeutics worth $1.15M as of Q3 2023.
  • Decheng Capital Management III (Cayman) left its Mersana Therapeutics share count unchanged in Q3 2023.
  • Mersana Therapeutics made up 0.38% of Decheng Capital Management III (Cayman)'s portfolio in Q3 2023, its #23 holding.
  • Decheng Capital Management III (Cayman) first reported a position in Mersana Therapeutics in Q1 2022 and has held it in 7 quarters since.
  • Decheng Capital Management III (Cayman)'s Mersana Therapeutics position peaked at $6.11M in Q3 2022.
  • 128 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.